Elsevier

Matrix

Volume 13, Issue 2, March 1993, Pages 95-102
Matrix

Direct Evidence for Active Metalloproteinases Mediating Matrix Degradation in Interleukin 1-Stimulated Human Articular Cartilage

https://doi.org/10.1016/S0934-8832(11)80068-5Get rights and content

Abstract

When adult human articular cartilage was maintained in organ culture in the presence of interleukin 1β, increased destruction of the extracellular matrix was observed, as judged by increased type II collagen degradation in situ determined immunohistochemically and the increased release of proteoglycan into the culture medium. Concomitant with these changes was the increased release of latent metalloproteinases into the culture medium. Culture of cartilage in the presence of a peptidylhydroxamate metalloproteinase inhibitor indicated a key role for the active forms of these enzymes in situ, since it produced a marked reduction in both proteoglycan release and collagen degradation. This compound had no detectable cytotoxic effects in organ culture and did not reduce the secretion of the metalloproteinases. The results of this study provide direct evidence that the latent metalloproteinase precursors, whose release is greatly stimulated by interleukin 1, are indeed activated to some degree and participate in cartilage matrix degradation.

References (31)

  • J.-J. Wu et al.

    Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage

    J. Biol. Chem.

    (1991)
  • W.P. Arend et al.

    Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis

    Arthritis Rheum.

    (1990)
  • I.K. Campbell et al.

    Human articular cartilage secretes characteristic metal-dependent proteinases upon stimulation by mononuclear cell factor

    J. Rheumatol.

    (1986)
  • I.K. Campbell et al.

    The action of human articular cartilage metalloproteinase on proteoglycan and link protein

    Similarities between in situ and in vitro degradation products. Biochem. J.

    (1986)
  • C.B. Caputo et al.

    Protease inhibitors decrease rabbit cartilage degradation after meniscectomy

    J. Ortho p. Res.

    (1988)
  • Cited by (94)

    • Delivery of anti-inflammatory peptides from hollow PEGylated poly(NIPAM) nanoparticles reduces inflammation in an ex vivo osteoarthritis model

      2017, Journal of Controlled Release
      Citation Excerpt :

      Pathological persistent activation of immune cells such as macrophages causes sustained release of pro-inflammatory cytokines such as interleukin-1 (IL-1) [4,5], interleukin-6 (IL-6) [6–8], and tumor necrosis factor-alpha (TNF-α) [8] which can aggravate or accelerate damage to the surrounding tissues. The elevated levels of inflammatory cytokines result in upregulation of proteolytic enzymes that degrade key components of the extracellular matrix such as aggrecan and collagen [9,10], facilitating penetration of inflammatory factors deeper into the cartilage. Initial treatment of OA often includes orally administered anti-inflammatory compounds such as non-steroidal anti-inflammatory drugs (NSAIDs) or newer compounds that inhibit specific pro-inflammatory cytokines such as Enbrel or Humira (both targeting TNF-α [11]) and Kineret (targeting IL-1 [12]).

    • The role of proteases in pathologies of the synovial joint

      2008, International Journal of Biochemistry and Cell Biology
    • Inflammatory Basis of Spinal Pain

      2007, Interventional Spine E-Book: An Algorithmic Approach
    View all citing articles on Scopus
    3

    Present address: Rheumatology Research, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.

    4

    Present address: Genetics Unit, Shriners Hospital, Montreal, Quebec, Canada.

    5

    Present address: St. Paul's Hospital, Vancouver, British Columbia, Canada.

    6

    Present address: Ciba Geigy, Summit, NJ, USA.

    7

    Dr. J. S. Mort, Joint Diseases Laboratory, Shriners Hospital for Crippled Children, 1529 Cedar Avenue, Montreal, Quebec, Canada H3G 1A6.

    View full text